pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
235
stories
Jul 8, 26
Novartis cuts New Jersey jobs; OTR, LG Chem explore China cancer drugs
endpoints
Jul 8, 26
STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
stat
Jul 7, 26
Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first half
endpoints
Jul 7, 26
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
biopharma dive
Jul 7, 26
STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
stat
Jul 6, 26
STAT+: Online GLP-1 prescriptions are often fast, easy — and low on clinical oversight
stat
Jul 6, 26
Novartis to acquire ADC developer in a deal worth up to $1.5B
biopharma dive
Jul 6, 26
STAT+: Four major biotech updates to catch up on
stat
Jul 6, 26
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
stat
Jul 6, 26
Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
endpoints
Jul 2, 26
Sandoz launches direct-to-consumer platform with growth disorder drug
endpoints
Jun 30, 26
These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
biopharma dive
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 17, 26
A new Westlake-backed biotech takes aim at migraines
biopharma dive
Jun 15, 26
STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end
stat
Jun 15, 26
Covid vaccination cut risk of adverse heart events, large study finds
stat
Jun 15, 26
STAT+: Lilly’s Ajax acquisition may have been worth it
stat
Jun 12, 26
STAT+: Prometheus raises $12 billion in capital for artificial engineers
stat
Jun 12, 26
STAT+: At hospital finance conference, a call to end the friction that’s keeping costs high
stat
Jun 11, 26
STAT+: An obesity drug deep-dive, and peptides move mainstream
stat
Jun 11, 26
Nonprofit buys experimental cancer drug to maintain patient access
stat
Jun 11, 26
Study highlights influence of socioeconomic status on children’s brain development
stat
Jun 11, 26
STAT+: Abridge inks deals with Nvidia and Lilly
stat
Jun 11, 26
STAT+: A suspicious denial pattern in Medicare Advantage
stat
Jun 11, 26
Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy
endpoints
Jun 11, 26
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
biopharma dive
Jun 11, 26
STAT+: Novartis doubles down on molecular glue strategy
stat
Jun 11, 26
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
biopharma dive
Jun 11, 26
STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
stat
Jun 10, 26
Novartis and Orionis strike second molecular glue deal for $40M upfront
endpoints
← prev
page 7 of 8
next →
